VRTXVertex Pharmaceuticals
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. 10-K, Item 1
- Employees
- 6,400
- Headquarters
- Boston, MA
- CEO
- Reshma Kewalramani
- Next results
- around Feb 11, 2027
What VRTX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Facts only; most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans adopted or ended
12 plans still running: Alan Garber, Bruce Sachs, Joy Liu, Nancy Thornberry, Sangeeta Bhatia, Charles F. Wagner, Jr., Carmen Bozic, Kristen Ambrose, Jeffrey Leiden, Reshma Kewalramani, Duncan McKechnie.
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Alan Garber Director |
Adopted 10b5-1 plan | Aug 27, 2026 | up to 5,320 | Jul 30, 2027 | 10-Q Nov 3, 2026 |
| Bruce Sachs Director |
Adopted 10b5-1 plan | Aug 26, 2026 | up to 9,888 | Jul 20, 2027 | 10-Q Nov 3, 2026 |
| Joy Liu EVP, Chief Legal Officer |
Adopted 10b5-1 plan | Aug 21, 2026 | up to 20,764 | May 3, 2027 | 10-Q Nov 3, 2026 |
| Nancy Thornberry Director |
Adopted 10b5-1 plan | Aug 15, 2026 | up to 2,571 | Jul 30, 2027 | 10-Q Nov 3, 2026 |
| Sangeeta Bhatia Director |
Adopted 10b5-1 plan | Aug 13, 2026 | up to 1,189 | Jul 30, 2027 | 10-Q Nov 3, 2026 |
| Charles F. Wagner, Jr. EVP, Chief Operating & Financial Officer |
Adopted 10b5-1 plan | Aug 10, 2026 | up to 15,286 | Jul 30, 2027 | 10-Q Nov 3, 2026 |
| Carmen Bozic EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer |
Adopted 10b5-1 plan | Aug 6, 2026 | up to 16,915 | Jul 30, 2027 | 10-Q Nov 3, 2026 |
| Kristen Ambrose SVP, Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 6, 2026 | up to 5,422 | Apr 30, 2027 | 10-Q Nov 3, 2026 |
| Jeffrey Leiden Executive Chairman |
Adopted 10b5-1 plan | Aug 5, 2026 | up to 18,411 | Nov 4, 2027 | 10-Q Nov 3, 2026 |
| Reshma Kewalramani Chief Executive Officer and President, Director |
Adopted 10b5-1 plan | Aug 5, 2026 | up to 47,800 | Dec 1, 2027 | 10-Q Nov 3, 2026 |
| Duncan McKechnie EVP, Chief Commercial Officer |
Adopted 10b5-1 plan | Nov 25, 2025 | up to 17,367 | Nov 13, 2026 | 10-K Feb 13, 2026 |
| Carmen Bozic EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer |
Adopted 10b5-1 plan | Nov 20, 2025 | up to 34,733 | Nov 2, 2026 | 10-K Feb 13, 2026 |
| Amit Sachdev EVP, Chief Patient and External Affairs Officer |
Adopted 10b5-1 plan | Nov 18, 2025 | up to 70,498 | Oct 30, 2026 | 10-K Feb 13, 2026 |
| Reshma Kewalramani Chief Executive Officer and President |
Adopted 10b5-1 plan | Nov 17, 2025 | up to 40,000 | Nov 16, 2026 | 10-K Feb 13, 2026 |
| Ourania "Nia" Tatsis EVP, Chief Regulatory and Quality Officer |
Adopted 10b5-1 plan | Aug 21, 2025 | up to 24,301 | Jul 31, 2026 | 10-Q Nov 4, 2025 |
| E. Morrow "Morrey" Atkinson, III EVP, Chief Technical Operations Officer, Head of Biopharmaceuitcal Sciences and Manufacturing Operations |
Adopted 10b5-1 plan | Aug 11, 2025 | up to 12,709 | Apr 30, 2026 | 10-Q Nov 4, 2025 |
| Kristen Ambrose SVP, Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 8, 2025 | up to 7,539 | Aug 3, 2026 | 10-Q Nov 4, 2025 |
| Jeffrey Leiden Executive Chairman |
Adopted 10b5-1 plan | Aug 6, 2025 | up to 144,644 | Jan 21, 2026 | 10-Q Nov 4, 2025 |
| Carmen Bozic EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer |
Adopted 10b5-1 plan | May 30, 2025 | up to 19,404 | Nov 21, 2025 | 10-Q Nov 4, 2025 |
| Sangeeta Bhatia Director |
Adopted 10b5-1 plan | May 27, 2025 | up to 1,116 | May 8, 2026 | 10-Q Aug 5, 2025 |
| Charles F. Wagner, Jr. EVP, Chief Operating & Financial Officer |
Adopted 10b5-1 plan | May 9, 2025 | up to 23,532 | Feb 6, 2026 | 10-Q Aug 5, 2025 |
| Jonathan Biller EVP, Chief Legal Officer |
Adopted 10b5-1 plan | Feb 24, 2025 | up to 22,217 | Feb 27, 2026 | 10-Q May 6, 2025 |
| Amit Sachdev EVP, Chief Patient and External Affairs Officer |
Adopted 10b5-1 plan | Feb 21, 2025 | up to 48,505 | Jan 30, 2026 | 10-Q May 6, 2025 |
| Ourania "Nia" Tatsis EVP, Chief Regulatory and Quality Officer |
Adopted 10b5-1 plan | Nov 22, 2024 | up to 11,270 | Oct 31, 2025 | 10-K Feb 13, 2025 |
| Charles F. Wagner, Jr EVP, Chief Financial Officer |
Adopted 10b5-1 plan | Aug 8, 2024 | up to 6,298 | Aug 1, 2025 | 10-Q Nov 5, 2024 |
| David Altshuler EVP, Chief Scientific Officer |
Adopted 10b5-1 plan | Aug 8, 2024 | up to 30,510 | Aug 1, 2025 | 10-Q Nov 5, 2024 |
| Kristen Ambrose SVP, Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 8, 2024 | up to 4,914 | Aug 1, 2025 | 10-Q Nov 5, 2024 |
| Jeffrey Leiden Executive Chairman |
Adopted 10b5-1 plan | May 10, 2024 | up to 11,355 | Aug 31, 2025 | 10-Q Aug 2, 2024 |
| Sangeeta Bhatia Director |
Adopted 10b5-1 plan | May 9, 2024 | up to 2,339 | May 9, 2025 | 10-Q Aug 2, 2024 |
| Ourania "Nia" Tatsis EVP, Chief Regulatory and Quality Officer |
Adopted 10b5-1 plan | Feb 29, 2024 | up to 9,484 | 427 days | 10-Q May 7, 2024 |
| Carmen Bozic EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer |
Adopted 10b5-1 plan | Feb 27, 2024 | up to 13,680 | 339 days | 10-Q May 7, 2024 |
| Charles F. Wagner, Jr. EVP, Chief Financial Officer |
Adopted 10b5-1 plan | Feb 26, 2024 | up to 6,500 | 340 days | 10-Q May 7, 2024 |
| E. Morrow "Morrey" Atkinson, III EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations |
Adopted 10b5-1 plan | Feb 22, 2024 | up to 25,290 | 372 days | 10-Q May 7, 2024 |
| Jonathan Biller EVP, Chief Legal Officer |
Adopted 10b5-1 plan | Feb 13, 2024 | up to 9,825 | 442 days | 10-Q May 7, 2024 |
| Bruce Sachs Director |
Adopted 10b5-1 plan | Feb 12, 2024 | up to 12,368 | 382 days | 10-Q May 7, 2024 |
| Reshma Kewalramani Chief Executive Officer and President |
Adopted 10b5-1 plan | Feb 7, 2024 | up to 96,388 | 468 days | 10-Q May 7, 2024 |
| Bastiano Sanna EVP, Chief of Cell and Genetic Therapies |
Adopted 10b5-1 plan | Aug 25, 2023 | up to 32,833 | 350 days | 10-Q Nov 7, 2023 |
| E. Morrow “Morrey” Atkinson III EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations |
Adopted 10b5-1 plan | Aug 22, 2023 | up to 9,224 | 252 days | 10-Q Nov 7, 2023 |
| Charles F. Wagner, Jr. EVP, Chief Financial Officer |
Adopted 10b5-1 plan | Aug 18, 2023 | up to 6,000 | 357 days | 10-Q Nov 7, 2023 |
| Reshma Kewalramani President, Chief Executive Officer and Director |
Adopted 10b5-1 plan | Aug 11, 2023 | up to 27,330 | 370 days | 10-Q Nov 7, 2023 |
| Jeffrey M. Leiden Executive Chairman |
Adopted 10b5-1 plan | Aug 4, 2023 | up to 40,454 | 650 days | 10-Q Nov 7, 2023 |
| Carmen Bozic EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer |
Adopted 10b5-1 plan | May 30, 2023 | up to 33,905 | 246 days | 10-Q Aug 2, 2023 |
| David Altshuler EVP, Global Research and Chief Scientific Officer |
Adopted 10b5-1 plan | May 10, 2023 | up to 32,896 | 373 days | 10-Q Aug 2, 2023 |
| Sangeeta Bhatia Director |
Adopted 10b5-1 plan | May 10, 2023 | up to 1,194 | 366 days | 10-Q Aug 2, 2023 |
| Amit Sachdev EVP, Chief Patient Officer |
Adopted 10b5-1 plan | May 9, 2023 | up to 40,128 | 377 days | 10-Q Aug 2, 2023 |
| Ourania Tatsis EVP, Chief Regulatory and Quality Officer |
Adopted 10b5-1 plan | May 9, 2023 | up to 11,783 | 358 days | 10-Q Aug 2, 2023 |
| Terrence Kearney Director |
Adopted 10b5-1 plan | May 9, 2023 | up to 10,000 | 234 days | 10-Q Aug 2, 2023 |
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 2, 2023.
Form 144 notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Kewalramani Reshma Officer, Director |
11,866 | $6,307,135 | ESPP Purchase; Restricted Stock Vesting | adopted Aug 5, 2026 | none found |
| Aug 27, 2026 | Bruce I. Sachs Director |
1,210 | $662,536 | Acquired as a gift | none given | none found |
| Jul 2, 2026 | Tatsis Ourania Officer |
1,500 | $787,485 | Restricted Stock Vesting | adopted Aug 21, 2025 | 1,500 shares from Jul 2, 2026 |
| Jul 2, 2026 | McKechnie Duncan Officer |
1,541 | $799,779 | Restricted Stock Vesting | adopted Nov 25, 2025 | 1,541 shares from Jul 2, 2026 |
| Jul 1, 2026 | Liu Joy Officer |
828 | $416,244 | Restricted Stock Vesting | adopted Nov 25, 2025 | 828 shares from Jul 1, 2026 |
| Jun 26, 2026 | Bozic Carmen Officer |
596 | $287,570 | Restricted Stock Vesting | adopted Nov 20, 2025 | 596 shares from Jun 26, 2026 |
| Jun 18, 2026 | Bozic Carmen Officer |
1,020 | $471,413 | Restricted Stock Vesting | adopted Nov 20, 2025 | 1,616 shares from Jun 18, 2026 |
| Jun 15, 2026 | Bozic Carmen Officer |
4,062 | $1,827,900 | Restricted Stock Vesting | adopted Nov 20, 2025 | 5,678 shares from Jun 15, 2026 |
| Jun 5, 2026 | Bozic Carmen Officer |
1,745 | $785,250 | Restricted Stock Vesting | adopted Nov 20, 2025 | 7,423 shares from Jun 5, 2026 |
| Jun 1, 2026 | Liu Joy Officer |
828 | $364,245 | Restricted Stock Vesting | adopted Nov 25, 2025 | 1,656 shares from Jun 1, 2026 |
| May 29, 2026 | Bozic Carmen Officer |
1,974 | $888,300 | Restricted Stock Vesting | adopted Nov 20, 2025 | 9,397 shares from May 29, 2026 |
| May 15, 2026 | Bozic Carmen Officer |
1,354 | $613,971 | Restricted Stock Vesting | adopted Nov 20, 2025 | 5,073 shares from May 15, 2026 |
| May 15, 2026 | Bunnage Mark E. Officer |
33 | $14,964 | ESPP Purchase | adopted Nov 26, 2025 | 33 shares from May 15, 2026 |
| May 12, 2026 | Bozic Carmen Officer |
6,988 | $3,144,600 | Restricted Stock Vesting | adopted Nov 20, 2025 | 12,061 shares from May 12, 2026 |
| May 6, 2026 | Biller Jonathan Officer |
5,193 | $2,203,149 | Restricted Stock Vesting | none given | none found |
| May 4, 2026 | Bhatia Sangeeta N. Director |
318 | $134,746 | Restricted Stock Vesting | adopted May 27, 2025 | 318 shares from May 4, 2026 |
| May 1, 2026 | Liu Joy Officer |
1,104 | $469,222 | Restricted Stock Vesting | adopted Nov 25, 2025 | 1,104 shares from May 1, 2026 |
| Apr 1, 2026 | Liu Joy Officer |
978 | $439,288 | Restricted Stock Vesting | adopted Nov 25, 2025 | 1,104 shares from May 1, 2026 |
| Mar 27, 2026 | Bozic Carmen Officer |
2,329 | $1,050,263 | Restricted Stock Vesting | adopted Nov 20, 2025 | none found |
| Mar 13, 2026 | Bozic Carmen Officer |
2,329 | $1,122,089 | Restricted Stock Vesting | adopted Nov 20, 2025 | none found |
| Mar 11, 2026 | McKechnie Duncan Officer |
2,633 | $1,312,340 | Restricted Stock Vesting | adopted Nov 25, 2025 | none found |
| Mar 4, 2026 | McKechnie Duncan Officer |
2,437 | $1,158,306 | Restricted Stock Vesting | adopted Nov 25, 2025 | none found |
| Mar 2, 2026 | Liu Joy Officer |
892 | $442,396 | Restricted Stock Vesting | adopted Nov 25, 2025 | none found |
| Feb 27, 2026 | Kewalramani Reshma Officer, Director |
40,000 | $19,738,905 | Restricted Stock Vesting | adopted Nov 17, 2025 | none found |
| Feb 27, 2026 | Bozic Carmen Officer |
2,329 | $1,118,642 | Restricted Stock Vesting | adopted Nov 20, 2025 | none found |
| Feb 25, 2026 | McKechnie Duncan Officer |
4,910 | $2,394,365 | ESPP Purchase; Restricted Stock Vesting | adopted Nov 25, 2025 | none found |
| Feb 25, 2026 | Tatsis Ourania Officer |
260 | $126,451 | Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Feb 25, 2026 | Bunnage Mark E. Officer |
620 | $301,537 | Restricted Stock Vesting | adopted Nov 26, 2025 | none found |
| Feb 25, 2026 | Atkinson Edward Morrow III Officer |
668 | $324,882 | Restricted Stock Vesting | adopted Aug 11, 2025 | none found |
| Feb 25, 2026 | Sachdev Amit Officer |
1,846 | $897,802 | Restricted Stock Vesting | adopted Nov 18, 2025 | none found |
| Feb 25, 2026 | Biller Jonathan Officer |
945 | $459,601 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Feb 19, 2026 | Sachdev Amit Officer |
58,613 | $27,479,576 | Option Granted - 02/06/2018; Option Granted - 02/06/2019; Restricted Stock Vesting | adopted Nov 18, 2025 | none found |
| Feb 18, 2026 | Tatsis Ourania Officer |
368 | $174,314 | Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Feb 18, 2026 | Biller Jonathan Officer |
1,244 | $589,258 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Feb 18, 2026 | Bunnage Mark E. Officer |
1,182 | $559,890 | Restricted Stock Vesting | adopted Nov 26, 2025 | none found |
| Feb 18, 2026 | Atkinson Edward Morrow III Officer |
817 | $386,997 | Restricted Stock Vesting | adopted Aug 11, 2025 | none found |
| Feb 17, 2026 | Bunnage Mark E. Officer |
2,437 | $1,192,814 | Restricted Stock Vesting | adopted Nov 26, 2025 | none found |
| Feb 17, 2026 | Tatsis Ourania Officer |
609 | $298,081 | Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Feb 17, 2026 | Biller Jonathan Officer |
2,476 | $1,211,903 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Feb 17, 2026 | Atkinson Edward Morrow III Officer |
2,031 | $994,093 | Restricted Stock Vesting | adopted Aug 11, 2025 | none found |
| Feb 13, 2026 | Biller Jonathan Officer |
988 | $493,012 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Feb 13, 2026 | Bhatia Sangeeta N. Director |
266 | $133,000 | Restricted Stock Vesting | adopted May 27, 2025 | none found |
| Feb 13, 2026 | Tatsis Ourania Officer |
1,500 | $749,992 | Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Feb 11, 2026 | Biller Jonathan Officer |
1,925 | $886,328 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Feb 11, 2026 | Atkinson Edward Morrow III Officer |
1,751 | $806,213 | Restricted Stock Vesting | adopted Aug 11, 2025 | none found |
| Feb 11, 2026 | Bunnage Mark E. Officer |
2,021 | $930,529 | Restricted Stock Vesting | adopted Nov 26, 2025 | none found |
| Feb 11, 2026 | Tatsis Ourania Officer |
466 | $214,560 | Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Jan 7, 2026 | Tatsis Ourania Officer |
4,500 | $2,137,455 | ESPP Purchase; Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Jan 6, 2026 | WAGNER CHARLES F JR Officer |
9,532 | $4,394,252 | Options Granted - 04/10/2019 | adopted May 9, 2025 | none found |
| Dec 3, 2025 | WAGNER CHARLES F JR Officer |
7,000 | $3,227,000 | Restricted Stock Vesting | adopted May 9, 2025 | none found |
| Dec 3, 2025 | WAGNER CHARLES F JR Officer |
7,000 | $3,157,000 | Restricted Stock Vesting | adopted May 9, 2025 | none found |
| Dec 3, 2025 | Tatsis Ourania Officer |
4,500 | $2,024,955 | ESPP Purchase; Restricted Stock Vesting | adopted Aug 21, 2025 | none found |
| Dec 3, 2025 | Biller Jonathan Officer |
347 | $155,803 | Restricted Stock Vesting | adopted Feb 24, 2025 | none found |
| Dec 3, 2025 | JEFFREY M LEIDEN Director, Officer |
63,781 | $27,626,740 | Exercise of Stock Options | adopted Aug 6, 2025 | none found |
| Nov 20, 2025 | CARNEY LLOYD Director |
800 | $341,088 | Stock Award | none given | none found |
| Nov 17, 2025 | Atkinson Edward Morrow III Officer |
2,500 | $1,086,450 | Restricted Stock Vesting | adopted Aug 11, 2025 | none found |
| Nov 14, 2025 | JEFFREY M LEIDEN Director, Officer |
53,604 | $23,292,010 | Exercise of Stock Options | adopted Aug 6, 2025 | none found |
| Nov 13, 2025 | JEFFREY M LEIDEN Director, Officer |
19,688 | $8,548,333 | Exercise of Stock Options | adopted Aug 6, 2025 | none found |
From the Form 144 XML filed with the SEC, since Nov 13, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Work on VRTX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.